AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12753341 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin (600 mg/day) for 24 weeks and IFN-alpha2b alone for the next 24 weeks (R2: 48 patients)
Number of subjects: 297
Study 12753341 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 24 weeks and then IFN-alpha2b alone for the next 24 weeks (R3: 104 patients)
Number of subjects: 297
Study 12753341 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 48 weeks (R4: 103 patients)
Number of subjects: 297
Study 12753341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin dose below 10.6 mg/kg/day
Number of subjects: 297
Study 12753341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin dose over 10.6 mg/kg/day
Number of subjects: 297
Study 12753341 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 297
Study 10671847 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg
Number of subjects: 62
Study 10671847 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 300 microg
Number of subjects: 62
Study 10671847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 62
Study 9187104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole (2.5 mg once daily for 7 days)
Number of subjects: 11
Study 9187104 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated postmenopausal breast cancer patients, N=9)
Number of subjects: 11
Study 8126259 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin with milk
Number of subjects: 6
Study 8126259 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin with water
Number of subjects: 6
Study 2880069 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52063 (80 mg)
Number of subjects: 6
Study 2880069 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52063 (120 mg)
Number of subjects: 6
Study 2880069 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52063 (80 mg and 120 mg)
Number of subjects: 6
Study 2880069 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52063 (in vitro)
Number of subjects: 6
Study 2880069 — intervention group
Group type: COMPARATOR
Intervention: ADP (in vitro)
Number of subjects: 6
Study 30638635 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (website, Fitbit One, text messaging)
Number of subjects: 76
Study 30638635 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 76
Study 30638635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 76
Study 30638635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 76
Study 30638635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory outcomes
Number of subjects: 76
Study 30597865 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (PROHIGH: 2.9 g·kg−1·d−1)
Number of subjects: 16
Study 30597865 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein diet (PROMOD: 1.8 g·kg−1·d−1)
Number of subjects: 16
Study 26789541 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg silodosin once daily for 4 weeks
Number of subjects: 34
Study 26789541 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin once daily for 4 weeks
Number of subjects: 34
Study 26789541 — intervention group
Group type: EXPERIMENTAL
Intervention: silodosin
Number of subjects: 34
Study 26789541 — intervention group
Group type: COMPARATOR
Intervention: tamsulosin
Number of subjects: 34
Study 24253615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 83
Study 24253615 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 83
Study 22111894 — intervention group
Group type: EXPERIMENTAL
Intervention: London Stroke Carer Training Course
Number of subjects: 900
Study 22111894 — intervention group
Group type: COMPARATOR
Intervention: Usual care according to national guidelines
Number of subjects: 900
Study 19998527 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 17804327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts with porcelain fused to metal crowns
Number of subjects: 80
Study 17804327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts with lithium disilicate crowns
Number of subjects: 80
Study 17804327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts with fiber‐reinforced composite crowns
Number of subjects: 80
Study 17804327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts with zirconia crowns
Number of subjects: 80
Study 17804327 — intervention group
Group type: COMPARATOR
Intervention: Without fiber posts with porcelain fused to metal crowns
Number of subjects: 80
Study 17804327 — intervention group
Group type: COMPARATOR
Intervention: Without fiber posts with lithium disilicate crowns
Number of subjects: 80
Study 17804327 — intervention group
Group type: COMPARATOR
Intervention: Without fiber posts with fiber‐reinforced composite crowns
Number of subjects: 80
Study 17804327 — intervention group
Group type: COMPARATOR
Intervention: Without fiber posts with zirconia crowns
Number of subjects: 80
Study 15086358 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine 1 microg x kg(‐1) min(‐1)
Number of subjects: 12
Study 15086358 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine 3 microg x kg(‐1) min(‐1)
Number of subjects: 12
Study 15086358 — intervention group
Group type: COMPARATOR
Intervention: placebo (NaCl 0.9%)
Number of subjects: 12
Study 11020505 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastomere biopsy followed by blastomere nucleus conversion into metaphase chromosomes
Number of subjects: 19
Study 8636880 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions of anger
Number of subjects: 22
Study 8636880 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions of fear
Number of subjects: 22
Study 1314260 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 120 mg/day
Number of subjects: 20
Study 1314260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg/day
Number of subjects: 20
Study 4043678 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 8
Study 3715441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 97
Study 3715441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 97
Study 31525334 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 31525334 — intervention group
Group type: COMPARATOR
Intervention: Noninsertive Sham Acupuncture
Number of subjects: 80
Study 30064923 — intervention group
Group type: EXPERIMENTAL
Intervention: History of psoriasis
Number of subjects: 1563
Study 30064923 — intervention group
Group type: COMPARATOR
Intervention: No history of psoriasis (Control)
Number of subjects: 1563
Study 28923035 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional position cast immobilization
Number of subjects: 0
Study 28923035 — intervention group
Group type: COMPARATOR
Intervention: Volar flexion-ulnar deviation position cast immobilization
Number of subjects: 0
Study 26026400 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF)
Number of subjects: 157
Study 23928836 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (20 mg orally, twice a day for at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days)
Number of subjects: 42
Study 23928836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23928836 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 42
Study 20189916 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial intervention using CD‐ROM (BPIC)
Number of subjects: 71
Study 20189916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 18345369 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone based asthma management (six telephone calls over 6 months)
Number of subjects: 71
Study 18345369 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 71
Study 16550952 — intervention group
Group type: EXPERIMENTAL
Intervention: Algosteril
Number of subjects: 50
Study 16550952 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl acetal (Merocel)
Number of subjects: 50
Study 14711068 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed initial assessment including obesity-focused history, physical examination, and selected laboratory and diagnostic tests
Number of subjects: 0
Study 10867543 — intervention group
Group type: EXPERIMENTAL
Intervention: HDhep (heparin anticoagulation)
Number of subjects: 10
Study 10867543 — intervention group
Group type: COMPARATOR
Intervention: HDcit (trisodium citrate anticoagulation)
Number of subjects: 10
Study 10867543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data for HDhep and HDcit
Number of subjects: 10
Study 9327192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (250 lipoproteinlipase releasing units, two capsules twice daily for 176 days on average)
Number of subjects: 107
Study 9327192 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (400 mg tablets, one tablet three times a day for 180 days on average)
Number of subjects: 107
Study 7900387 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulation with Poly-A Poly-U
Number of subjects: 50
Study 7900387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunomodulation)
Number of subjects: 50
Study 3710287 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal therapy with 500 mg metronidazole once a day for 7 days
Number of subjects: 38
Study 3710287 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy with 400 mg metronidazole twice daily for 7 days
Number of subjects: 38
Study 3710287 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal therapy
Number of subjects: 38
Study 3710287 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy
Number of subjects: 38
Study 29684433 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oxygen (initially 2 L/min, later adjusted to 4 L/min if tolerated)
Number of subjects: 61
Study 29684433 — intervention group
Group type: COMPARATOR
Intervention: Control oxygen (>10 L/min)
Number of subjects: 61
Study 27821114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (9,000 lux)
Number of subjects: 150
Study 27821114 — intervention group
Group type: COMPARATOR
Intervention: Dim red light therapy (100 lux)
Number of subjects: 150
Study 24326079 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisdom nominees
Number of subjects: 94
Study 24326079 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 94
Study 22324528 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set with 70% abnormal cases
Number of subjects: 100
Study 22324528 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set with 50% abnormal cases
Number of subjects: 100
Study 22324528 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set with 30% abnormal cases
Number of subjects: 100
Study 20430138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary education using Australia's National Heart Foundation Tick symbol
Number of subjects: 49
Study 20430138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary education using Food Standards Australia and New Zealand's low-salt guideline of 120 mg sodium/100 g food
Number of subjects: 49
Study 18540778 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 12
Study 18540778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15935269 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (GIC-Ketac-Fil)
Number of subjects: 8
Study 15935269 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified GIC (RM-GIC-Vitremer)
Number of subjects: 8
Study 15935269 — intervention group
Group type: COMPARATOR
Intervention: Composite resin (CR-Z250) (negative control)
Number of subjects: 8
Study 12966258 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine administered epidurally (Kepi group)
Number of subjects: 45
Study 12966258 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine administered intravenously (Kiv group)
Number of subjects: 45
Study 12966258 — intervention group
Group type: COMPARATOR
Intervention: 10ml normal saline administered epidurally (Ctr group)
Number of subjects: 45
Study 11339006 — intervention group
Group type: EXPERIMENTAL
Intervention: Young runners (age 20-24)
Number of subjects: 20
Study 11339006 — intervention group
Group type: EXPERIMENTAL
Intervention: Old runners (age 52.9)
Number of subjects: 20
Study 11339006 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers aged 21.6)
Number of subjects: 20
Study 11339006 — intervention group
Group type: COMPARATOR
Intervention: Control group (men aged 52.9)
Number of subjects: 20
Study 8772558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily for 6 months)
Number of subjects: 89
Study 8772558 — intervention group
Group type: COMPARATOR
Intervention: Etidronate (400 mg daily for 6 months)
Number of subjects: 89
Study 1334248 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g daily of oatbran
Number of subjects: 29
Study 1334248 — intervention group
Group type: COMPARATOR
Intervention: Oat-free control diet
Number of subjects: 29
Study 6397334 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pivmecillinam plus 250 mg pivampicillin twice daily for 5 days
Number of subjects: 58
Study 6397334 — intervention group
Group type: COMPARATOR
Intervention: 250 mg amoxycillin plus 125 mg clavulanate 3-times daily for 5 days
Number of subjects: 58
Study 31741955 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 1004
Study 31741955 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy
Number of subjects: 1004
Study 28973115 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification intervention
Number of subjects: 200
Study 28973115 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 200
Study 26791606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolipolysis and diet
Number of subjects: 45
Study 26791606 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser lipolysis and diet
Number of subjects: 45
Study 26791606 — intervention group
Group type: COMPARATOR
Intervention: Only diet
Number of subjects: 45
Study 25082132 — intervention group
Group type: EXPERIMENTAL
Intervention: Steering Teens Safe intervention (45-minute session, four follow-up phone sessions, DVD, workbook)
Number of subjects: 145
Study 25082132 — intervention group
Group type: EXPERIMENTAL
Intervention: Steering Teens Safe intervention
Number of subjects: 145
Study 25082132 — intervention group
Group type: EXPERIMENTAL
Intervention: Steering Teens Safe intervention (successful communication)
Number of subjects: 145
Study 25082132 — intervention group
Group type: COMPARATOR
Intervention: Control (standard brochure about safe driving)
Number of subjects: 145
Study 22051103 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 374
Study 22051103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 374
Study 19458488 — intervention group
Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (0.2 mg)
Number of subjects: 0
Study 19458488 — intervention group
Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (0.6 mg)
Number of subjects: 0
Study 19458488 — intervention group
Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (2 mg)
Number of subjects: 0
Study 19458488 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 19458488 — intervention group
Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (0.6 mg) in nonhuman primates
Number of subjects: 0
Study 17536922 — intervention group
Group type: EXPERIMENTAL
Intervention: School nurses providing PCPs with accurate peak flow data and requesting an AAP
Number of subjects: 0
Study 17536922 — intervention group
Group type: COMPARATOR
Intervention: School nurses requesting an AAP via the students' parents without providing peak flow data
Number of subjects: 0
Study 15370062 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 190
Study 11747385 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic use of beta-adrenergic blockers
Number of subjects: 0
Study 11747385 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone and atrial overdrive pacing
Number of subjects: 0
Study 11747385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm management (electrical cardioversion, amiodarone)
Number of subjects: 0
Study 11747385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate management
Number of subjects: 0
Study 11747385 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0
Study 9576151 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stable angina
Number of subjects: 58
Study 9576151 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 58
Study 9576151 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with elevated total and LDL cholesterol
Number of subjects: 58
Study 9576151 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 58
Study 9576151 — intervention group
Group type: COMPARATOR
Intervention: Patients with stable angina
Number of subjects: 58
Study 9576151 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with markedly abnormal peripheral reflexes
Number of subjects: 58
Study 9576151 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tests of autonomic function
Number of subjects: 58
Study 7886749 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets
Number of subjects: 6
Study 7886749 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated bed nets
Number of subjects: 6
Study 2905252 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 75 mg twice daily
Number of subjects: 59
Study 2905252 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg at bedtime
Number of subjects: 59
Study 2905252 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg at night
Number of subjects: 59
Study 2905252 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg post cenam nocte (PCN)
Number of subjects: 59
Study 2905252 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg post cenam nocte (PCN)
Number of subjects: 59
Study 2905252 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 300 mg post cenam nocte (PCN)
Number of subjects: 59
Study 29404770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn100kVp acquisition
Number of subjects: 78
Study 29404770 — intervention group
Group type: COMPARATOR
Intervention: 120kVp acquisition
Number of subjects: 78
Study 28259610 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib plus gemcitabine
Number of subjects: 142
Study 28259610 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 142
Study 26151176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Food Record (mFR) application for dietary assessment
Number of subjects: 0
Study 26151176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for a Healthy and Sustainable Diet Index
Number of subjects: 0
Study 24481570 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean final dose 14.4 mg/day)
Number of subjects: 68
Study 22104618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with bevacizumab
Number of subjects: 267
Study 22104618 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine with placebo
Number of subjects: 267
Study 19577277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy (at least 5 cycles)
Number of subjects: 367
Study 19577277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting median survival and 5-year survival probability
Number of subjects: 367
Study 19577277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy
Number of subjects: 367
Study 17578360 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-3801
Number of subjects: 97
Study 15215806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day)
Number of subjects: 279
Study 15215806 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.5)
Number of subjects: 279
Study 15215806 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic treatment
Number of subjects: 279
Study 11222822 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drugs used for disease control during pregnancy
Number of subjects: 0
Study 11222822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy counselling and collaboration with obstetricians and perinatologists
Number of subjects: 0
Study 11222822 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility rate and optimal timing of conception
Number of subjects: 0
Study 11222822 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of disease flares during lupus pregnancy
Number of subjects: 0
Study 11222822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy course and fetal outcome
Number of subjects: 0
Study 11222822 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive advice
Number of subjects: 0
Study 10765970 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 14
Study 10765970 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 14
Study 10765970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9221559 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 38
Study 9221559 — intervention group
Group type: COMPARATOR
Intervention: Peroral chemotherapy (Hydroxyurea or Busulphan)
Number of subjects: 38
Study 2139409 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d Gallopamil (group 1)
Number of subjects: 117
Study 2139409 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d Metoprolol (group 2)
Number of subjects: 117
Study 2139409 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Atenolol and 20 mg Nifedipine daily (group 3)
Number of subjects: 117